Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Research & Development (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Research & Development for 5 consecutive years, with $11.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 7.14% to $11.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $53.6 million, a 6.49% increase, with the full-year FY2024 number at $56.4 million, up 35.09% from a year prior.
  • Research & Development was $11.6 million for Q3 2025 at Werewolf Therapeutics, down from $13.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $15.9 million in Q4 2022 to a low of $4.8 million in Q1 2021.
  • A 5-year average of $11.8 million and a median of $12.5 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: skyrocketed 127.22% in 2022, then tumbled 39.16% in 2023.
  • Werewolf Therapeutics' Research & Development stood at $13.4 million in 2021, then grew by 18.35% to $15.9 million in 2022, then tumbled by 39.16% to $9.6 million in 2023, then skyrocketed by 62.99% to $15.7 million in 2024, then decreased by 26.03% to $11.6 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Research & Development are $11.6 million (Q3 2025), $13.1 million (Q2 2025), and $13.1 million (Q1 2025).